Literature DB >> 18722357

Immunohistochemical localization of CB1 cannabinoid receptors in frontal cortex and related limbic areas in obese Zucker rats: effects of chronic fluoxetine treatment.

J Zarate1, I Churruca, E Echevarría, L Casis, M López de Jesús, L Saenz del Burgo, J Sallés.   

Abstract

In the present study, we report on the application of two specific polyclonal antibodies to different intracellular domains of the CB1 cannabinoid receptor to define the expression of the neural CB1 cannabinoid receptor at the histochemical level in frontal cortex and related limbic areas of the obese Zucker rats. Higher levels of CB1 receptor expression in frontal, cingulated and piriform cortex, without differences in temporal, parietal and occipital cortex, were observed in obese Zucker rats, with respect to their lean littermates. CB1 phosphorylated receptor (CB1-P) levels were also higher in frontal, temporal, parietal and occipital cortex in obese rats with respect to lean controls. Potential involvement of brain cortical CB1 cannabinoid receptors in the long-term effects of fluoxetine was studied. Experimental animals were administered with fluoxetine (10 mg/kg, i.p.) daily for 3 weeks, whereas the control group was given 0.9% NaCl solution. In obese Zucker rats, a significant decrease in CB1 receptor levels, measured by western blot, was observed in brain cortex after fluoxetine treatment. Immunostaining for CB1 receptor expression was also carried out, showing a significant decrease in the density of neural cells positive for CB1 receptor in frontal, cingulate and piriform cortex, without changes in parietal, temporal and occipital regions. Regional prosencephalic immunostaining for CB1-P receptor level showed a significant decrease in the density of stained neural cells in frontal, temporal and parietal cortex, without changes in cingulated, piriform and occipital cortex. These results suggest the involvement of endocannabinoid system in the chronic effects of fluoxetine, especially in the frontal cortex.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18722357     DOI: 10.1016/j.brainres.2008.07.100

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  5 in total

1.  Cortical adrenoceptor expression, function and adaptation under conditions of cannabinoid receptor deletion.

Authors:  B A S Reyes; A F Carvalho; P Szot; D J Kalamarides; Q Wang; L G Kirby; E J Van Bockstaele
Journal:  Exp Neurol       Date:  2017-03-21       Impact factor: 5.330

2.  Cannabinoid modulation of cortical adrenergic receptors and transporters.

Authors:  B A S Reyes; J C Rosario; P M T Piana; E J Van Bockstaele
Journal:  J Neurosci Res       Date:  2009-12       Impact factor: 4.164

3.  Antidepressants and changes in concentration of endocannabinoids and N-acylethanolamines in rat brain structures.

Authors:  Irena Smaga; Beata Bystrowska; Dawid Gawliński; Bartosz Pomierny; Piotr Stankowicz; Małgorzata Filip
Journal:  Neurotox Res       Date:  2014-03-21       Impact factor: 3.911

4.  Fluoxetine Facilitates Fear Extinction Through Amygdala Endocannabinoids.

Authors:  Ozge Gunduz-Cinar; Shaun Flynn; Emma Brockway; Katherine Kaugars; Rita Baldi; Teniel S Ramikie; Resat Cinar; George Kunos; Sachin Patel; Andrew Holmes
Journal:  Neuropsychopharmacology       Date:  2015-10-30       Impact factor: 7.853

5.  The bidirectional effect of prelimbic 5-hydroxytryptamine type-4 (5-HT4) receptors on ACPA-mediated aversive memory impairment in adult male Sprague-Dawley rats.

Authors:  Nargol Ahmadi-Mahmoodabadi; Masoumeh Emamghoreishi; Mohammad Nasehi; Mohammad-Reza Zarrindast
Journal:  Iran J Basic Med Sci       Date:  2021-06       Impact factor: 2.699

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.